Neonatal and carrier screening for rare diseases: how innovation challenges screening criteria worldwide

Screening for rare diseases first began more than 50 years ago with neonatal bloodspot screening (NBS) for phenylketonuria, and carrier screening for Tay-Sachs disease, sickle cell anaemia and β-thalassaemia. NBS’s primary aim is health gain for children, while carrier screening enables autonomous r...

Descripción completa

Detalles Bibliográficos
Autores principales: Cornel, Martina C., Rigter, Tessel, Jansen, Marleen E., Henneman, Lidewij
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141077/
https://www.ncbi.nlm.nih.gov/pubmed/33074550
http://dx.doi.org/10.1007/s12687-020-00488-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141077/
https://www.ncbi.nlm.nih.gov/pubmed/33074550
http://dx.doi.org/10.1007/s12687-020-00488-y

Ejemplares similares